{"disease":{"id":"complicated-skin-and-skin-structure-infections","name":"complicated skin and skin structure infections"},"drugs":{"marketed":[{"drug_id":"chembl-chembl1200962","indication_name":"Uncomplicated Skin and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"cefpodoxime","indication_name":"Uncomplicated skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Uncomplicated Skin and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01104662","title":"Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true}],"total":1},"guidelines":[{"drug_id":"linezolid","guideline_body":"FDA label","recommendation":"Linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"meropenem","guideline_body":"FDA label","recommendation":"Meropenem for Injection, USP is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to specified pathogens.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"meropenem","guideline_body":"FDA label","recommendation":"Meropenem for Injection, USP is indicated for the treatment of complicated appendicitis and peritonitis caused by specified pathogens.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"meropenem","guideline_body":"FDA label","recommendation":"Meropenem for Injection, USP is indicated for the treatment of bacterial meningitis caused by specified pathogens.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}